2型糖尿病患者的疾病负担研究及替代治疗分析——以磺脲类药物治疗为例

Economic Burden of T2DM Patients and Analysis on the Alternative Treatment among Insured Urban Population——Taking Sulfonylurea Treatment as an Example

目的:探索使用磺脲类药物的我国2型糖尿病住院患者的疾病负担情况及用DPP-4抑制剂(如沙格列汀)进行替代治疗的费用变化。方法 :对2011-2012年使用磺脲类药物的患者进行描述性研究,提取关键数据对沙格列汀替代磺脲类药物进行影响分析。结果 :4628例患者中,合并心脑血管疾病的患者组次均住院总费用最高,为7826.82±5767.51元。格列美脲为磺脲类药物中使用最多的药物。服用沙格列汀替代格列美脲每年将为社会节省5000多万元的药品费用支出。结论 :沙格列汀替代格列美脲后可节省大量的医疗费用,缓解T2DM患者经济负担。

Objective： To study direct medical cost in T2DM patients using sulfonylureas in China and to explore the cost changes when sulfonylurea was replaced by DPP-4 inhibitor such as Saxagliptin. Methods： Critical data from database and literatures were used to analyze the impact of drug substitution on medical cost. Results： 4628 T2DM inpatients using Sulfonylurea were included and the cost in patients with cardio- and cerebrovascular diseases （540 inpatients） were the highest （7826.82±5767.5 lyuan）. Glimepiride is the most frequently used Sulfonylurea drug. Drug expenditure of over 50 million Yuan would be saved by Saxagliptin substitution annually. Conclusion： Economic burden in T2DM patients with cardio- and cerebrovascular diseases is considerable. Medical cost would be reduced after Saxagliptin replacing Sulfonyurea.